One-quarter of patients with multiple sclerosis report having used cannabis therapeutically and nearly one out of six (16 percent) currently use it to treat symptoms of the disease, according to survey data commissioned by the North American Research Committee on MS.
Over 5,600 MS patients participated in the survey, the results of which were presented last week at the Consortium of Multiple Sclerosis Center 2015 Annual Meeting.
Most subjects who had tried marijuana said it mitigated disease symptoms, such as spasticity or pain. Only five percent of patients surveyed said that cannabis said it did not provide some level of relief.
Those with more advanced symptoms of MS were more likely to report using cannabis therapeutically.
Of those surveyed, 82 percent said that they would consider cannabis therapy if it were a legal option in their state.
Clinical trials have previously reported that cannabis inhalation is superior to placebo in reducing pain and spasticity in patients with treatment-resistant MS. Other studies indicate that long-term use of cannabinoid therapy may potentially modify MS progression.
Previously survey data published in the journal Neurology reported that 14 percent of MS patients used cannabis for symptom management.
Story Source: The above story is based on materials provided by NORML
Note: Materials may be edited for content and length